The manufacturing of active pharmaceutical ingredients (APIs) is a complex, specialised activity, requiring the expert intertwining of chemistry and engineering. Historically, this was performed by large pharmaceutical companies, who saw value in taking the drug seamlessly from drug discovery to large-scale manufacture and keeping the whole process under one roof. In parallel to this, contract manufacturing organisations (CMOs) arose to support production when additional capacity was needed or specialised chemistry required.
This webinar aims to present an expert review of the last 40 years of the CMO industry for small molecules. In addition to in-depth analysis by Cambrex, performed over the period 1975-2015, a series of primary research interviews with industry experts was undertaken. In total, the views of 10 industry veterans, each of whom had no less than 25 years’ experience in the CMO industry, have been presented.
This webinar aims to present the audience with an historic overview of how contract manufacturing has evolved since the early days of being a niche, opportunistic industry, with just a few suppliers where most manufacturing was still routinely performed in-house within large pharmaceutical plants, to one that blossomed into a $50-60bn enterprise, where outsourced pharmaceutical manufacturing has now become the rule rather than the exception.
After looking back over the last 40 years, Cambrex will then offer a forward-looking opinion on what to expect for the CMO industry in the coming 5 years from 2016 through to 2020. The webinar will then culminate in an unveiling of the new Cambrex brand – with a focus on Active Ingredients | Dynamic People – and how the organization is well positioned to become the leading CMO in small molecule manufacturing by 2020.This webinar will:
- Learn about the last 40 years of the API manufacturing industry with respect to small molecules.
- Understand the opinion of industry experts as they give valuable insights into their own experiences during 1975-2015
- Explore how the industry has evolved to the booming business it is today and the outlook for the CMO market over the next 5 years (2016-2020).
- Gain an opportunity to see the unveiling of the new Cambrex brand and learn about its ambition to become the leading small molecule API manufacturer
Dr. Matthew Moorcroft, VP of Global Marketing, Cambrex
Alex Maw, Director, Marketing and Communications, Cambrex